Company intelligence / Profile preview

Chrysalis BioTherapeutics, Inc.

Galveston, Texas, United Stateschrysbio.com ↗

Ownership: Private
Development stage: Phase 1

Overview

TP508 (Chrysalin/rusalatide acetate) has demonstrated human safety and efficacy in clinical trials for diabetic foot ulcers and fracture repair. The FDA has approved Chrysalis' IND application to proceed with Phase I human clinical trials for ARDS. The company has received funding from NIH and BARDA for development of TP508 as a nuclear countermeasure.

Therapeutic areas: PulmonologyEndocrinologyOtherDermatologyRheumatologyNeurologyInfectious Diseases
Modalities: Peptide therapeutics
Industry: Biotech

Drug pipeline

1 asset

rusalatide

Preclinical

Partnerships

National Institute of Allergy and Infectious Disease (NIAID)Biomedical Advanced Research Development Authority (BARDA)

Beyond the preview

Go deeper on Chrysalis BioTherapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chrysalis BioTherapeutics, Inc..

Explore the full profile